Lv4
460 积分 2022-07-20 加入
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
2天前
已完结
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
2天前
已完结
T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy
4天前
求助中
Diagnosis and treatment of autoimmune thyroid diseases
7天前
已完结
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
1个月前
已完结
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
1个月前
已完结
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
1个月前
已完结
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
1个月前
已完结
Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy
1个月前
已完结
A Novel Universal CD7-Targeted CAR-T Cell Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma
1个月前
已关闭
皖公网安备34019202002308
